Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING NA

Machine Learning Prediction of Possible Central Line Associated Blood Stream Infections and Rate of Reduction

NCT07108660 · View on ClinicalTrials.gov ↗

Study Summary

Prospective, multi-center, cluster-randomized trial of a hospital Infection Preventionist (IP)-led quality improvement study to provide clinical teams with just-in-time clinical education and reinforcement of existing best practices recommendations based on the output of a possible Central Line Associated Blood Stream Infection (CLABSI) Machine Learning (ML) prediction model. The objective is to determine whether providing this model to Infection Preventionists will decrease the CLABSI rates versus routine clinical practice.

Interventions

  • BEHAVIORAL Infection Preventionist Led Best Practices Reminders

Study Locations (19)

California

  • St. Mary Medical Center — Apple Valley
  • Providence Saint Joseph Medical Center — Burbank
  • St. Jude Medical Center — Fullerton
  • Providence Holy Cross Medical Center — Mission Hills
  • Mission Hospital — Mission Viejo
  • Queen of the Valley Medical Center — Napa
  • St. Joseph Hospital — Orange
  • Santa Rosa Memorial Hospital — Santa Rosa
  • Providence Cedars-Sinai Tarzana Medical Center — Tarzana

Washington

  • Swedish Medical Center Edmonds — Edmonds
  • Providence Regional Medical Center Everett — Everett
  • Providence St. Peter Hospital — Olympia
  • Kadlec Regional Medical Center — Richland
  • Swedish Medical Center Cherry Hill — Seattle
  • Swedish Medical Center First Hill — Seattle
  • Providence Sacred Heart Medical Center — Spokane

Alaska

  • Providence Alaska Medical Center — Anchorage

Oregon

  • Providence St. Vincent Medical Center — Portland

Texas

  • Covenant Medical Center — Lubbock

Trial Details

FieldValue
Enrollment Target 17,800 participants
Start Date 2025-07-01
Est. Completion 2027-12
Phase NA

Sponsor

Swedish Medical Center

11 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07108660

The ClinicalTrials.gov registry entry for NCT07108660 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 17,800 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Swedish Medical Center, which has 11 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Central Line Associated Blood Stream Infections (CLABSI) appearing as the primary indexed condition, and to 1 intervention — of which Infection Preventionist Led Best Practices Reminders is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT07108660 reports 19 study locations spanning 5 distinct geographic areas — top geographies include California, Washington, Alaska. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT07108660 about?

NCT07108660 is a clinical study titled "Machine Learning Prediction of Possible Central Line Associated Blood Stream Infections and Rate of Reduction". Prospective, multi-center, cluster-randomized trial of a hospital Infection Preventionist (IP)-led quality improvement study to provide clinical teams with just-in-time clinical education and reinforcement of existing best practices recommendations based on the output of a possible Central Line Asso...

What is the current status of trial NCT07108660?

This trial is currently recruiting. It is a NA study. The enrollment target is 17,800 participants. The study started on 2025-07-01. Estimated completion is 2027-12.

What conditions does trial NCT07108660 study?

This clinical trial studies the following conditions: Central Line Associated Blood Stream Infections (CLABSI). These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT07108660?

The interventions under investigation include: Infection Preventionist Led Best Practices Reminders (BEHAVIORAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT07108660?

This trial is sponsored by Swedish Medical Center, which has 11 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT07108660 being conducted?

This trial has 19 study locations across Alaska, California, Oregon, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial